MDRPEDIA RECORDTITAN · TIER ILIVING
Ugur Sahin
Oncology · BioNTech · Mainz, Turkey
- h-index (OpenAlex)
- 103
- Papers on record
- 10
- Citations to these papers
- 31,795
- Stature
- Tier I
EVIDENCE RECORD
What this record is built on
Compared with the register: Surgery · Turkey · How it works
I · SCHOLARSHIP
- h-index
- 103 · 71st pct
- Papers on record
- 10
- Citations received
- 31,795
II · PRACTICE
- Licence
- Not yet checked
- Board certification
- —
- Registration ID
- —
- Institutions
- 2
III · LEARNING & TEACHING
- Trainees traced
- Not yet traced
- Mentors traced
- Not yet traced
- Invited talks
- —
IV · PEER STANDING
- Honours
- 2
- Techniques pioneered
- 1
- Ethics mark
- Not yet audited
Not on this record by design:Star ratingsAnonymous reviewsPaid placement
Record
Ugur Sahin is a Turkish-German oncologist and immunologist who co-founded BioNTech and co-developed the Pfizer-BioNTech COVID-19 mRNA vaccine, the first mRNA vaccine authorized worldwide.
IN PLAIN WORDS
- Pioneered the BNT162b2 mRNA COVID-19 vaccine, a technique still used by doctors worldwide
- Research is cited 32K+ times by other doctors and scientists, indicating significant influence on medical research
- Currently at BioNTech in Mainz, Turkey
What they treat and study
SPECIALTIES
CLINICAL KNOWLEDGE AND PROCEDURES
Institutions
- BioNTech
- University Medical Center of the Johannes Gutenberg University Mainz
QUESTIONS YOU MIGHT ASK AT A FIRST VISIT
- Is a procedure needed now, or can medicines and lifestyle changes help first?
- What are the risks and benefits of each option for someone like me?
- How many similar cases does your team see, and who will be involved in my care?
- Who do I contact if symptoms come back after treatment?
Landmark papers
- Papers on record
- 10
- Citations received
- 31,795
PUBLISHED IN New England Journal of Medicine · Nature · Nature Reviews Drug Discovery · Proceedings of the National Academy of Sciences
- 2020Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineNew England Journal of Medicinedoi 10.1056/nejmoa203457715,346 citations
- 2020Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine CandidatesNew England Journal of Medicinedoi 10.1056/nejmoa20279062,715 citations
- 2017Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancerNaturedoi 10.1038/nature230032,413 citations
- 2014mRNA-based therapeutics — developing a new class of drugsNature Reviews Drug Discoverydoi 10.1038/nrd42782,356 citations
- 2020COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responsesNaturedoi 10.1038/s41586-020-2814-72,030 citations
Show all 10 papersShow fewer papers
- 2016Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapyNaturedoi 10.1038/nature183001,705 citations
- 2020Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adultsNaturedoi 10.1038/s41586-020-2639-41,579 citations
- 1997A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screeningProceedings of the National Academy of Sciencesdoi 10.1073/pnas.94.5.19141,239 citations
- 2015Mutant MHC class II epitopes drive therapeutic immune responses to cancerNaturedoi 10.1038/nature144261,231 citations
- 2023Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancerNaturedoi 10.1038/s41586-023-06063-y1,181 citations
Honours
- —Bundesverdienstkreuz (Federal Cross of Merit)
- —Mustafa Prize
Techniques pioneered
- BNT162b2 mRNA COVID-19 vaccine
Career
- 2008Co-founded BioNTech
- 2020Developed BNT162b2 COVID-19 vaccineCreated the first authorized mRNA vaccine in partnership with Pfizer
Lineage
We haven't traced this physician's mentors and trainees yet. If you trained with them, you can add to the record.Contribute lineage
FOR THE DOCTOR
Are you Ugur Sahin?
Claim this record to correct details, add your lineage and teaching, and embed your seal. Claims are checked against your registration before anything changes.